Table 4.

Genomic impact of outcomes in MF patients undergoing allo-HCT

Lead author/ referenceDisease and no. of patientsNo. of genes testedConditioning regimenSurvival dataNotes
Kröger 201730  169 MF patients who underwent allo-HCT 16 MAC: 2%
RIC: 98% 
5-y PFS = 48%
5-y OS = 52% 
CALR mutation associated with improved OS
IDH2 mutation associated with inferior RFS
ASXL1 mutation associated with inferior RFS 
Tamari 201932  101 MF patients who underwent allo-HCT 585 MAC: 18%
RIC: 82% 
5-y RFS = 51%
5-y OS = 52% 
U2AF1 mutation associated with inferior OS and RFS
DNMT3A mutation associated with inferior RFS
≥3 somatic mutations not associated with worse OS compared with ≤2 somatic mutations
MAC associated with improved OS
High-risk MIPSS70 not associated with inferior OS compared with intermediate-risk MIPSS70 
Ali 201933  110 MF patients who underwent allo-HCT 72 RIC: 100% 5-y PFS = 60%
5-y OS = 65% 
CBL mutation associated with inferior OS and DFS
U2AF1 mutation associated with increased NRM
MIPSS70 high-risk group with worse OS and DFS compared with intermediate-risk group
MIPSS70+ v2.0 very high-risk group with worse OS and DFS when compared with high-risk group. 
Stevens 202031  55 MF patients who underwent allo-HCT 54 MAC: 75%
RIC: 25% 
10-y OS in DIPSS+ low/Int-1 risk = 82%
10-y OS in DIPSS+ Int-2/high risk = 50%
10-y PFS in DIPSS+ low/Int-1 risk = 82%
10-y PFS in DIPSS+ Int-2/high risk = 46% 
≥3 somatic mutations in addition to JAK2 or CALR2 mutation associated with worse PFS in comparison with ≤2 mutations regardless of DIPSS+ score 
Lead author/ referenceDisease and no. of patientsNo. of genes testedConditioning regimenSurvival dataNotes
Kröger 201730  169 MF patients who underwent allo-HCT 16 MAC: 2%
RIC: 98% 
5-y PFS = 48%
5-y OS = 52% 
CALR mutation associated with improved OS
IDH2 mutation associated with inferior RFS
ASXL1 mutation associated with inferior RFS 
Tamari 201932  101 MF patients who underwent allo-HCT 585 MAC: 18%
RIC: 82% 
5-y RFS = 51%
5-y OS = 52% 
U2AF1 mutation associated with inferior OS and RFS
DNMT3A mutation associated with inferior RFS
≥3 somatic mutations not associated with worse OS compared with ≤2 somatic mutations
MAC associated with improved OS
High-risk MIPSS70 not associated with inferior OS compared with intermediate-risk MIPSS70 
Ali 201933  110 MF patients who underwent allo-HCT 72 RIC: 100% 5-y PFS = 60%
5-y OS = 65% 
CBL mutation associated with inferior OS and DFS
U2AF1 mutation associated with increased NRM
MIPSS70 high-risk group with worse OS and DFS compared with intermediate-risk group
MIPSS70+ v2.0 very high-risk group with worse OS and DFS when compared with high-risk group. 
Stevens 202031  55 MF patients who underwent allo-HCT 54 MAC: 75%
RIC: 25% 
10-y OS in DIPSS+ low/Int-1 risk = 82%
10-y OS in DIPSS+ Int-2/high risk = 50%
10-y PFS in DIPSS+ low/Int-1 risk = 82%
10-y PFS in DIPSS+ Int-2/high risk = 46% 
≥3 somatic mutations in addition to JAK2 or CALR2 mutation associated with worse PFS in comparison with ≤2 mutations regardless of DIPSS+ score 

DFS, disease-free survival; MAC, myeloablative conditioning; PFS, progression-free survival; RIC, reduced-intensity conditioning. See Tables 1 and 3 for expansion of other abbreviations.

or Create an Account

Close Modal
Close Modal